In breast cancer, the genomic-driven approach, that is, the selection of drugs matching tumor molecular alterations to treat patients with cancer7, has yet to demonstrate superiority to standard of care beyond targeting the estrogen receptor (ER) and HER2 pathways. Here, ESR1 is linked to neoplasm.